Please assess the completion status of the following clinical trial:

Trial Title: Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have signed consent for LAB03-0383~2. Pathologic documentation of NSCLC~3. Stage IIIA and IIIB (T4 satellite nodules or invasion into T4 structures but no malignant effusion) with all patients requiring mediastinoscopy positive N2, potentially resectable disease. N3 disease is excluded.~4. Measurable disease~5. Zubrod performance status of 0 or 1~6. Calculated post-resectional FEV1 of \> 40%~7. WBC\>4000/l, ANC\>1500/l, platelets \> 100,000/l~8. Serum creatinine \< 1.5 ULN or calculated creatinine \> 50 cc/min~9. Total serum bilirubin \<1.5 x ULN or SGPT or SGOT \< 2 X ULN~10. The following must be completed within 28 days of registration: CT scan of the chest and upper abdomen to include the adrenals. Mediastinoscopy to document ipsilateral nodal involvement and exclude N3 disease Blood tests, and pulmonary function tests The following must be completed within 2 months of registration: Pet scan If a CT PET is done more than 28 days, only the CT needs to be repeated and a bone scan to rule out bone metastases~Exclusion Criteria:~1. No prior chemotherapy or radiation for NSCLC~2. No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the patient has been disease-free for at least five years. If patient is suspected or known to have basal or squamous skin cancer, this maybe treated after induction chemotherapy is completed at the time of thoracotomy.~3. No post-obstructive pneumonia or other serious infection or other serious underlying medical condition that would impair ability of patient to receive protocol treatment, including prior allergic reactions to drugs containing cremophor.~4. Pregnant or nursing women may not participate

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy + Tarceva (Type: ACTIVE_COMPARATOR): None
- Chemotherapy Alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).